Current Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2000 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED): A single-arm phase 2 trial.
Journal Article Cancer · December 15, 2025 INTRODUCTION: Esophagogastric cancers are common and carry a poor prognosis. A standard option for locally advanced disease has been neoadjuvant chemoradiation (CRT) followed by surgical resection. The primary goal of this study was to investigate whether ... Full text Link to item CiteCirculating Tumor DNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion.
Journal Article Ann Surg Oncol · October 2025 BACKGROUND: Hepatic arterial infusion (HAI) chemotherapy is an expanding treatment for patients with unresectable colorectal liver metastases (uCRLM). This study examined circulating tumor DNA (ctDNA) as a novel biomarker to prognosticate oncologic outcome ... Full text Link to item CiteRecent Grants
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinom
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2025 - 2030[M24-977] A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gas
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2029A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Clinical TrialPrincipal Investigator · Awarded by Arcus Biosciences · 2022 - 2027View All Grants
Education, Training & Certifications
State University of New York, Buffalo ·
2000
M.D.